Form 4: Moderna Director Abbas Hussain Receives RSU Grant

Moderna Director Abbas Hussain was granted 8,371 restricted stock units, vesting in May 2027 or at the next annual meeting.

Summary

• Director Abbas Hussain received an equity grant of 8,371 restricted stock units (RSUs).
• The RSUs convert to common stock on a one-for-one basis.
• The grant is subject to continued service requirements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard director compensation event.

Risks

• None identified; this is a standard director compensation event.

Future Outlook

The RSUs are scheduled to vest in full on May 6, 2027, or upon the date of the next Annual Meeting of Shareholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the biotechnology sector to ensure director retention and alignment with shareholder interests.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with compensation practices at large-cap pharmaceutical and biotech companies such as Pfizer, Merck, and Amgen.

Stakeholder Impact

• Minimal impact on shareholders as this represents a standard director compensation arrangement.

Next Steps

• Vesting of the 8,371 RSUs on May 6, 2027, or the next Annual Meeting of Shareholders.

Key Dates

Keywords

Moderna, MRNA, Director Compensation, Restricted Stock Units, Insider Transaction, Equity Grant